GPR119

GPR119

A gene on chromosome Xq26.1 that encodes an orphan G protein-coupled receptor.
References in periodicals archive ?
Moreover, the G proteincoupled receptor 55 (GPR55) and G protein-coupled receptor 119 (GPR119) are currently being postulated as new members of the cannabinoid receptor family (47) as they have recently been identified as being targets for the endocannabinoids.
One was the gene for G-protein coupled receptor 119 (GPR119) a previously hot target for novel diabetes drugs.
Dr mml explains that during the early days of the Human Genome Project, the GPR119 gene, coding for a 7TM receptor, was identified and shown to have a unique pattern of expression in pancreatic islets and in some regions of the gastrointestinal tract in humans.
Our data have shown, for the first time, that GPR119 is selectively expressed in alpha cells, not beta cells, and is most likely involved in regulating glucagon secretion not insulin secretion directly.
If the new ICMC islet cell gene expression directory had been available when researchers first thought of developing GPR119 agonists, they would have realised they were on the wrong track.
Global Markets Direct's, 'Glucose-Dependent Insulinotropic Receptor (G-Protein Coupled Receptor 119 or GPR119) - Pipeline Review, H1 2016', provides in depth analysis on Glucose-Dependent Insulinotropic Receptor (G-Protein Coupled Receptor 119 or GPR119) targeted pipeline therapeutics.
The report provides comprehensive information on the Glucose-Dependent Insulinotropic Receptor (G-Protein Coupled Receptor 119 or GPR119), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
* The report provides a snapshot of the global therapeutic landscape for Glucose-Dependent Insulinotropic Receptor (G-Protein Coupled Receptor 119 or GPR119)
will be presenting a 30-minute scientific presentation entitled "Creating and Using a Physiological Model to Support Development of a GPR119 Agonist Diabetes Therapy." The presentation will describe the development, testing, and use of a custom-designed Diabetes PhysioPD model, including use of the model to clarify mechanisms of action, support compound selection, select First-In-Human doses, and predict longer-term (HbA1c lowering) clinical outcomes.